cemiplimab
sanofi,regeneron
['cemiplimab', 'libtayo']
(constructive neoadjuvant libtayo (cemiplimab) monotherapy information in resectable cutaneous squamous cell carcinoma offered at esmo and printed in nejm | antibodies | information channels has been published on - 